Labiotech.eu

News and Trends 28 Nov 2022

STORM Therapeutics doses first patient with drug targeting solid tumors

STORM Therapeutics Ltd, announced today that the first patient in a phase 1 study had been dosed with a drug targeting solid tumors. The biotech company works on discovering and developing new small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The patient was dosed with STC-15, STORM’s clinical candidate. It […]

November 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive […]

November 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 25 Nov 2022

New function of CRISPR gene scissors discovered

For several years, the CRISPR/Cas9 gene scissors have been causing a sensation in science and medicine. Researchers from the Institute of Structural Biology at the University Hospital Bonn (UKB) in Germany and the Medical Faculty of the University of Bonn, in cooperation with the partner University of St Andrews in Scotland and the European Molecular […]

November 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Nov 2022

Beyond Biotech podcast 24: Concarlo Therapeutics, Eversana, Carl Borrebaeck, SOTIO Biotech

This week, we have four interviews: Franjo Hanzl, vice president commercial development Europe at Eversana; Stacy Blain, founder and CEO of Concarlo Therapeutics; Jens Hennecke, chief business officer at SOTIO Biotech; and Carl Borrebaeck, chairman of the board of directors of Immunovia and professor at the Department of Immunotechnology at the University of Lund in […]

November 25, 2022

News and Trends 25 Nov 2022

XtalPi and CK Life Sciences partner on tumor vaccine R&D

XtalPi has entered into a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. The goal is to jointly develop a novel artificial intelligence (AI) tumor vaccine R&D platform. This will improve the discovery and design capabilities of tumor vaccines and accelerate development of more vaccine types. According to public information, […]

November 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

Gene therapy approval “game changer” in hemophilia B treatment

The approval of CSL’s gene therapy Hemgenix has ushered in a new era for hemophilia B treatment. With the addition of other approvals like Rocktavian and Upstaza, 2022 could be a turning point for the broader gene therapy field. Earlier this week, etranacogene dezaparvovec (Hemgenix) made history as the first gene therapy approved by the […]

November 24, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 24 Nov 2022

AI works on artificial DNA for future drug development

With the help of artificial intelligence (AI), researchers at Chalmers University of Technology in Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs […]

November 24, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

BC Platforms partners on AI-driven EU cancer data project

BC Platforms (BCP), a provider of healthcare data management and analytics, has been chosen as a key partner in a European Commission (EC) project. Under the EC’s Horizon Europe program, Helsinki University Hospital (HUS), has been awarded a contract to lead a €7 million ($7.2 million) consortium project termed ONCOVALUE. BCP will work with HUS […]

November 24, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

FDA gives IND approval for Ascletis Covid drug

Ascletis Pharma Inc. has revealed that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for Covid-19. The FDA has approved Ascletis to study the safety, tolerability and pharmacokinetics of ASC11 at various doses in healthy subjects […]

November 24, 2022 - 2 minutesmins - By Jim Cornall

health awareness day week month calendar

News and Trends 24 Nov 2022

New Labiotech Health Awareness Days listings page

Earlier this year, we added a page to the website with all of the global events and conferences taking place. It’s been very well received, and we’ve had plenty of messages telling us of events to add. Now, we’ve added a new resource to our site. It’s a list of all of the health and […]

November 24, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

BIA and Exopharm sign joint research agreement to develop integrated technology

Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […]

November 23, 2022 - 4 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has led to identify CLEC-1 as […]

November 23, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

STORM Therapeutics doses first patient with drug targeting solid tumors

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

New function of CRISPR gene scissors discovered

Beyond Biotech podcast 24: Concarlo Therapeutics, Eversana, Carl Borrebaeck, SOTIO Biotech

XtalPi and CK Life Sciences partner on tumor vaccine R&D

Gene therapy approval “game changer” in hemophilia B treatment

AI works on artificial DNA for future drug development

BC Platforms partners on AI-driven EU cancer data project

FDA gives IND approval for Ascletis Covid drug

New Labiotech Health Awareness Days listings page

BIA and Exopharm sign joint research agreement to develop integrated technology

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!